Table 1.
Patient demographics
| Demographics | Bevacizumab and irinotecan N = 52 |
|---|---|
| Median age (years) | 55 (33–65) |
| ECOG performance status | |
| 0 | 36 (69.2) |
| 1 | 12 (23.1) |
| 2 | 4 (7.7) |
| Primary site, no (%) | |
| Fallopian tube | 8 (15.4) |
| Ovarian | 44 (84.6) |
| Histology, no (%) | |
| Serous | 38 (73.1) |
| Endometrioid | 8 (15.4) |
| Mixed pattern | 6 (11.5) |
| Disease stage, no (%) | |
| II | 12 (23.1) |
| III | 26 (50.0) |
| IV | 14 (26.9) |
| Cytoreductive surgery, no (%) | |
| Yes | 42 (80.8) |
| No | 10 (19.2) |
| Prior regimen, no (%) | |
| 1 | 14 (27.0) |
| 2 | 32 (61.5) |
| 3 | 6 (11.5) |
ECOG Eastern Cooperative Oncology Group